Gyros AB and ACE BioSciences A/S reveal proteomics collaboration and begin field tests of prototype.

07-Jan-2002

Gyros AB announced today that its first product, due for launch later this year, will be tested in collaboration with ACE BioSciences at the proteomic company’s headquarters in Odense, Denmark.

ACE BioSciences focuses its expertise on functional proteomics and needs to prepare a large number of protein samples per week for analysis by MALDI mass spectrometry, a technique used for protein identification. The new product from Gyros is intended to improve and streamline sample preparation by integrating several steps into a single automated process. Large numbers of samples are prepared in parallel in a microlaboratory in the form of a CD. This industrial approach to sample preparation has so far resulted in a consistent improvement in sensitivity of the final MALDI analyses leading to more reliable identification of even low abundance proteins, a key benefit in proteomic research.

“As in any commercial operation, it is critical that the performance and quality of our products are tested under industrial working conditions,” explained Per Sjöberg, Executive Vice President Commercial Operations at Gyros, “ACE BioSciences fulfils this requirement perfectly and is positioned to give us high quality professional feedback.”

Ejvind Mortz, PhD., Chief Executive Officer of ACE BioSciences stated: ” As a functional proteomics company in a rapidly growing field, it is essential that we take advantage of the latest tools available to accelerate proteomic research. This collaboration not only gives Gyros an excellent opportunity to fine tune their product, but gives us early access to an exciting technology platform with great potential for adaptation to new applications. We have the chance to be closely involved in the development of products that can give us a strong competitive advantage.”

Sjöberg continued, ” We have clearly stated our intention to build up a range of products that enable the expanding proteomics market to benefit from our proprietary technology platform. The interest and enthusiasm of a proteomics company such as ACE BioSciences strongly supports this strategy and we are optimistic that this initial work will lead to new ideas and applications for our technology.”


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.